- NCT00082602
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameGalantamine hydrobromideProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment83% Female66%% White85%
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-ALZ-303Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)78
Supporting Documentation
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Additional Information
Please note: individual participant-level data are not available for this trial. Only the protocol, statistical analysis plan, and full clinical study report are available.